Pierschbacher, M. D.; Ruoslahti, E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984, 309, 30-33. (Pubitemid 14134132)
Ruoslahti, E. The RGD story: a personnal account. Matrix Biol. 2003, 22, 459-465.
Tamkun, J. W.; DeSimone, D. W.; Fonda, D.; Patel, R. S.; Buck, C.; Horwitz, A. F.; Hynes, R. O. Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell 1986, 46, 271-282.
Humphries, M. J. Integrin structure. Biochem. Soc. Trans. 2000, 28, 311-340.
Takagi, J.; Petre, B. M.; Walz, T.; Springer, T. A. Global conformational rearrangements in integrin extracellular domains in outside-in and outside-out signaling. Cell 2002, 110, 599-611.
Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110, 673-687.
Brooks, P. C.; Clark, R. A. F.; Cheresh, D. A. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994, 264, 569-571.
Duong, L. T.; Rodan, G. A. Integrin-mediated signaling in the regulation of osteoclast adhesion and activation. Front. Biosci. 1998, 3, d757-d768.
Petitclerc, E.; Stromblad, S.; Von Schakscha, T. L.; Mitjans, F.; Piutlats, J.; Montgommery, A. M.; Cheresh, D. A.; Brooks, P. C. Integrin αvβ3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res. 1999, 59, 2724-2730.
Kumar, C. C. Integrin αvβ3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr. Drug Targets 2003, 4, 123-131.
Dechantstreiter, M. A.; Planker, E.; Mathae, B.; Lohof, E.; Hoelzemann, G.; Jonczyk, A.; Goodman, S. L.; Kessler, H. N-Methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists. J. Med. Chem. 1999, 42, 3033-3040.
Keenan, R. M.; Miller, W. H.; Kwon, C.; Ali, F. E.; Callahan, J. F.; Calvo, R. R.; Hwang, S.-M.; Kopple, K. D.; Peishoff, C. E.; Samanen, J. M.; Wong, A. S.; Yuan, C.-K.; Huffman, W. F. Discovery of potent nonpeptide vitronectin receptor (αvβ3) antagonists. J. Med. Chem. 1997, 40, 2289-2292.
Miller, W. H.; Keenan, R. M.; Willette, R. N.; Lark, M. W. Identification and in vivo efficacy of small-molecule antagonists of integrin αvβ3 (the vitronectin receptor). Drug Discovery Today 2000, 5, 397-408.
Kerr, J. S.; Slee, A. M.; Mousa, S. A. The Rv integrin antagonists as novel anticancer agents: an update. Expert Opin. Investig. Drugs 2002, 11, 1765-1774.
Coleman, P. J.; Brashear, K. M.; Askew, B. C.; Hutchinson, J. H.; McVean, C. A.; Duong, L. T.; Feuston, B. P.; Fernandez-Metzler, C.; Gentile, M. A.; Hartman, G. D.; Kimmel, D. B.; Leu, C.-T.; Lipfert, L.; Merkle, K.; Pennypacker, B.; Prueksaritanont, T.; Rodan, G. A.; Wesolowski, G. A.; Rodan, S. B.; Duggan, M. E. Nonpeptide αvβ3 antagonists. Part 11: Discovery and preclinical evaluation of potent αvβ 3 antagonists for the prevention and treatment of osteoporosis. J. Med. Chem. 2004, 47, 4829-4837.
Dayam, R.; Aiello, F.; Deng, J.; Wu, Y.; Garofalo, A.; Chen, X.; Neamati, N. Discovery of small molecule integrin αvβ3 antagonists as novel anticancer agents. J. Med. Chem. 2006, 49, 4526-4534.
Thumshirn, G.; Hersel, U.; Goodman, S. L.; Kessler, H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chem. - Eur. J. 2003, 9, 2717-2725.
Nasongkla, N.; Shuai, X.; Ai, H.; Weinberg, B. D.; Pink, J.; Boothman, D. A.; Gao, J. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew. Chem., Int. Ed. 2004, 43, 6323-6327.
Temming, K.; Schiffelers, R. M.; Molema, G.; Kok, R. J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updates 2005, 8, 381-402.
Hersel, U.; Dahmen, C.; Kessler, H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 2003, 24, 4385-4415. (Pubitemid 36960136)
Siebers, M. C.; ter Brugge, P. J.; Walboomers, X. F.; Jansen, J. A. Integrins as liker proteins between osteoblasts and bone replacing materials. A critical review. Biomaterials 2005, 26, 137-146.
Lieb, E.; Hacker, M.; Tessmar, J.; Kunz-Schughart, L. A.; Fiedler, J.; Dahmen, C.; Hersel, U.; Kessler, H.; Schulz, M. B.; Göpferich, A. Mediating specific cell adhesion to low-adhesive diblock copolymers by instant modification with cyclic RGD peptides. Biomaterials 2005, 26, 2333-2341. (Pubitemid 39600687)
Ma, P. X. Biomimetic materials for tissue engineering. Adv. Drug Delivery Rev. 2008, 60, 184-198.
Marchand-Brynaert, J.; Detrait, E.; Noiset, O.; Boxus, T.; Schneider, Y.-J.; Remacle, C. Biological evaluation of RGD peptidomimetics, designed for the covalent derivatization of cell culture substrata, as potential promotors of cellular adhesion. Biomaterials 1999, 20, 1773-1782.
Biltresse, S.; Attolini, M.; Marchand-Bryanert, J. Cell adhesive PET membranes by surface grafting of RGD peptidomimetics. Biomaterials 2005, 26, 4576-4587.
Li, L.-S.; Rader, C.; Matsushita, M.; Das, S.; Barbas, C. F.; Lerner, R. A.; Sinha, S. C. Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices. J. Med. Chem. 2004, 47, 5630-5640.
Meyer, A.; Auernheimer, J.; Modlinger, A.; Kessler, H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 2006, 12, 2723-2747.
Patel, S.; Thakar, R. G.; Wong, J.; McLeod, S. D.; Li, S. Control of cell adhesion on poly(methyl methacrylate). Biomaterials 2006, 27, 2890-2897. (Pubitemid 43165758)
Auernheimer, J.; Zukowski, D.; Dahmen, C.; Kantlehner, M.; Enderle, A.; Goodman, S. L.; Kessler, H. Titanium implant materials with improved biocompatibity through coating with phosphonate-anchored cyclic RGD peptides. ChemBioChem 2005, 6, 2034-2040.
Dahmen, C.; Auernheimer, J.; Meyer, A.; Enderle, A.; Goodman, S. L.; Kessler, H. Improving implant materials by coating with nonpeptidic, highly specific integrin ligands. Angew. Chem., Int. Ed. 2004, 43, 6649-6652.
Curley, G. P.; Blum, H.; Humphries, M. J. Integrin antagonists. Cell. Mol. Life, Sci. 1999, 56, 427-441.
Hartman, G. D.; Egbertson, M. S.; Halczenko, W.; Laswell, W. L.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; Manno, P. D.; Lynch, R. J.; Zhang, G.; Chang, C. T.-C.; Gould, R. J. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 1992, 35, 4640-4642.
Boxus, T.; Touillaux, R.; Dive, G.; Marchand-Bryanert, J. Synthesis and evaluation of RGD peptidomimetics aimed at surface bioderivatization of polymer substrates. Bioorg. Med. Chem. 1998, 6, 1577-1595.
Biltresse, S.; Attolini, M.; Dive, G.; Cordi, A.; Tucker, G. C.; Marchand-Brynaert, J. Novel RDG-like molecules based on the tyrosine template: design, synthesis, and biological evaluation on isolated integrins αvβ3/αIIbβ3 and in cellular adhesion tests. Bioorg. Med. Chem. 2004, 12, 5379-5393.
Yamanaka, T.; Ohkudo, M.; Kuroda, S.; Nakamura, H.; Takahashi, F.; Aoki, T.; Mihara, K.; Seki, J.; Kato, M. Design, synthesis, and structure-activity relationships of potent GPIIb/IIIa antagonists: discovery of FK419. Bioorg.Med. Chem. 2005, 13, 4343-4352.
Duggan, M. E.; Duong, L. T.; Fisher, J. E.; Hamill, T.G.; Hoffman; Huff, W. F. J. R.; Ihle, N. C.; Leu, C.-T.; Nagy, R. M.; Perkins, J. J.; Rodan, S. B.; Wesolowski, G.; Whitman, D. B.; Zartman, A. E.; Rodan, G. A.; Hartman, G. D. Nonpeptide αvβ3 Antagonists. 1. Transformation of a Potent, Integrin-Selective αIIbβ3 Antagonist into a Potent αvβ3 Antagonist. J.Med. Chem. 2000, 43, 3736-3745.
Rockwell, A. L.; Rafalski, M.; Pitts, W. J.; Batt, D. G.; Petraitis, J. J.; DeGrado, W. F.; Mousa, S.; Jadhav, P. K. Rapid synthesis of RGD mimetics with isoxazoline scaffolds on solid phase: identification of αvβ3 antagonists lead compounds. Bioorg. Med. Chem. Lett. 1999, 9, 937-942.
Duggan, M. E.; Hutchinson, J. H. Ligands to the integrin receptor αvβ3. Expert Opin. Ther. Pat. 2000, 10, 1367-1383.
Coleman, P. J.; Duong, L. T. Ligands to the integrin receptor αvβ3. Expert Opin. Ther. Pat. 2002, 12, 1009-1021.
Cacciari, B.; Spalluto, G. Non peptidic αvβ 3 antagonists: Recent developments. Curr. Med. Chem. 2005, 12, 51-70.
Pilkington-Miksa, M. A.; Sarkar, S.; Writer, M. J.; Barker, S. E.; Shamlou, P. A.; Hart, S. L.; Hailes, H. C.; Tabor, A. B. Synthesis of bifonctional integrin-binding peptides containing PEG spacers of defined length for nonviral gene delivery. Eur. J. Org. Chem. 2008, 2900-2914.
Heckmann, D.; Meyer, A.; Laufer, B.; Zahn, G.; Stragies, R.; Kessler, H. Rational design of highly active and selective ligands for the α5β1 integrin receptor. ChemBioChem 2008, 9, 1397-1407.
Biltresse, S.; Descamps, D.; Henneuse-Boxus, C.; Marchand-Brynaert, J. Effect of the chemical nature and the length of spacer-arms on the covalent grafting of molecular probes at the surface of PET membranes. J. Polym. Sci., Part A: Polym. Chem. 2002, 40, 770-781. (Pubitemid 34210930)
Penso, M.; Albanese, D.; Landini, D.; Lupi, V.; Tricarico, G. Specific solvation as a tool for the N-chemoselective arylsulfonylation of tyrosine and (4-hydroxyphenyl)glycine methyl esters. Eur. J. Org. Chem. 2003, 4513-4517.
Brennauer, A.; Keller, M.; Freund, M.; Bernhardt, G.; Buschauer, A. Decomposition of 1-(ω-aminoalkanoyl)guanidines under alkaline conditions. Tetrahedron Lett. 2007, 48, 6996-6999.
Nguyen, C.; Ruda, G. F.; Schipani, A.; Kasinathan, G.; Leal, I.; Musso-Buendia, A.; Kaiser, H.; Brun, R.; Ruiz-Perez, L. M.; Sahlberg, B.-L.; Johanson, N. G.; Gonzalez-Pacanowska, D.; Gilbert, I. Acyclic Nucleoside Analogues as Inhibitors of Plasmodium falciparum dUTPase. J. Med. Chem. 2006, 49, 4183-4195.
Kim, K. S.; Qian, L. Fire-retardant and intumescent compositions for cellulosic material. Tetrahedron Lett. 1993, 34, 7677-7680.
Frederick, R.; Charlier, C.; Robert, S.; Wouters, J.; Masereel, B.; Pochet, L. Investigation of mechanism-based thrombin inhibitors: Implications of a highly conserved water molecule for the binding of coumarins within the S pocket. Bioorg. Med. Chem. Lett. 2006, 16, 2017-2021.
Botta, M.; Corelli, F.; Maga, G.; Manetti, F.; Renzulli, M.; Spadari, S. Research on anti-HIV-1 agents. Part 2: Solid-phase synthesis, biological evaluation and molecular modeling studies of 2,5,6- trisubstituted-4(3H)- pyrimidinones targeting HIV-1 reverse transcriptase. Tetrahedron 2001, 57, 8357-8367.
Marugan, J. J.; Manthey, C.; Anaclerio, B.; Lafrance, L.; Lu, T.; Markotan, T.; Leonard, K. A.; Crysler, C.; Eisennagel, S.; Dasgupta, M.; Tomczuk, B. Design, Synthesis, and Biological Evaluation of Novel Potent and Selective αvβ3/αIIbβ 3 Integrin Dual Inhibitors with Improved Bioavailability. Selection of the Molecular Core. J. Med. Chem. 2005, 48, 926-934.
Geneste, H.; Kling, A.; Lauterbach, A.; Graef, C. I.; Subkowski, T.; Hornberger, W. Preparation of dibenzo[b,e]azepines as αvβ 3 integrin ligands. Int. Patent WO 2002014320, 2002.
Heckmann, D.; Meyer, A.; Marinelli, L.; Zahn, G.; Stragies, R.; Kessler, H. Probing integrin selectivity: rational design of highly active and selective ligands for the α5β1 and α vβ3 integrin receptor. Ang. Chem., Int. Ed. 2007, 46, 3571-3574.
Lefrancois, J. M.; Heckmann, B. Preparation of pyrimidine amino acid derivatives as antagonists of the vitronectin receptor. French Patent FR 2870541, 2005.
Dormer, P. G.; Eng, K. K.; Farr, R. N.; Humphrey, G. R.; McWilliams, J. C.; Reider, P. J.; Sager, J. W.; Volante, R. P. Highly Regioselective Friedlaender Annulations with Unmodified Ketones Employing Novel Amine Catalysts: Syntheses of 2-Substituted Quinolines, 1,8-Naphthyridines, and Related Heterocycles. J. Org. Chem. 2003, 68, 467-477.
Ameer, F.; Giles, R. G. F.; Green, I. R.; Nagabhushana, K. S. The DDQ mediated cyclization products of some 2-hydroxy-3-(1′-alkenyl)-1,4- naphthoquinones. Synth. Commun. 2002, 32, 369-380.
Backes, J. R.; Koert, U. Stereoselective synthesis of the monomeric unit of SCH 351448. Eur. J. Org. Chem. 2006, 2777-2785.
Prabhakaran, P. C.; Gould, S. J.; Orr, G. R.; Coward, J. K. Synthesis of chirally deuteriated phthalimido-propanols and evaluation of their absolute stereochemistry. J. Am. Chem. Soc. 1988, 110, 5779-5784.
Kim, K. S.; Song, Y. H.; Lee, B. H.; Hahn, C. S. Efficient and selective cleavage of acetals and ketals using ferric chloride adsorbed on silica gel. J. Org. Chem. 1986, 51, 404-406.
Yong, Y. F.; Kowalski, J. A.; Lipton, M. A. Facile and Efficient Guanylation of Amines Using Thioureas and Mukaiyama's Reagent. J. Org. Chem. 1997, 62, 1540-1542.
Balicki, R.; Maciejewski, G. A mild and selective deoxygenation of N-oxides with ammonium formate as a catalytic hydrogen transfer agent. Synth. Commun. 2002, 32, 1681-1683.
Salvagnini, C.; Gharbi, S.; Boxus, T.; Marchand-Brynaert, J. Synthesis and evaluation of a small library of graftable thrombin inhibitors derived from (L)-arginine. Eur. J. Med. Chem. 2007, 42, 37-53.
Momtaz, M.; Rerat, V.; Gharbi, S.; Gerard, E.; Pourcelle, V.; Marchand-Brynaert, J. A graftable LDV peptidomimetic: design, synthesis and application to a blood filtration membrane. Bioorg. Med. Chem. Lett. 2008, 18, 1084-1090.
Takahashi, T.; Shiyama, T.; Hosoya, K.; Tanaka, A. Development of chemically stable solid phases for the target isolation with reduced nonspecific binding proteins. Bioorg. Med. Chem. Lett. 2006, 16, 447-450.
Adamczyk, M.; Fishpaugh, J. R.; Thiruvazhi, M. Concise synthesis of N-protected carboxyalkyl ether amines. Org. Prep. Proc. Int. 2002, 34, 326-331.
Chapman, R. G.; Ostuni, E.; Liang, M. N.; Yan, L.; Whitesides, G. M. Self-assembled monolayer surfaces that resist the adsorption of biological species. Int. Patent WO 2002006407, 2002.
Martinez, V.; Mecking, S.; Tassaing, T.; Besnard, M.; Moisan, S.; Moisan, S.; Cansell, F.; Aymonier, C. Dendritic core-shell macromolecules soluble in supercritical carbon dioxide. Macromolecules 2006, 39, 3978-3979. (Pubitemid 44021287)
Sulyok, G. A. G.; Gibson, C.; Goodman, S. L.; Hölzemann, G.; Wiesner, M.; Kessler, H. Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective αvβ3 integrin antagonists. J. Med. Chem. 2001, 44, 1938-1950.
Porté-Durrieu, M. C.; Guillemot, F.; Pallu, S.; Labrugère, C.; Brouillaud, B.; Bareille, R.; Amédée, J.; Barthe, N.; Dard, M.; Baquey, Ch. Cyclo-(DfKRG) peptide grafting onto Ti-6Al-4V: physical characterization and interest towards human osteoprogenitor cells adhesion. Biomaterials 2004, 25, 4837-4846. (Pubitemid 38561172)
Pallu, S.; Bourget, C.; Bareille, R.; Labrugere, C.; Dard, M.; Sewing, A.; Jonczyk, A.; Vernizeau, M.; Durrieu, M. C.; Amédée- Vilamitjana, J. The effect of cyclo-DfKRG peptide immobilization on titanium on the adhesion and differentiation of human osteoprogenitor cells. Biomaterials 2005, 26, 6932-6940. (Pubitemid 41095517)
Landegren, U. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J. Immunol. Methods 1984, 67, 379-388.
Pfaff, M.; Tangemann, K.; Müller, B.; Gurrath, M.; Müller, G.; Kessler, H.; Timpl, R.; Engel, J. Selective recognition of cyclic RGD peptides of NMR defined conformation by αIIbβ3, αvβ3, and α5β1 integrins. J. Biol. Chem. 1994, 269, 20233-20238.
Xiong, J.-P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S. L.; Arnaout, M. Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296, 151-155.
Moitessier, N.; Henry, C.; Maigret, B.; Chapleur, Y. Combining pharmacophore search, automated docking, and molecular dynamics simulations as a novel strategy for flexible docking. Proof of concept: docking of arginine-glycine-aspartic acid-like compounds into the αvβ 3 binding site. J. Med. Chem. 2004, 47, 4178-4187.
Manzoni, L.; Bassanini, M.; Belvisi, L.; Motto, I.; Scolastico, C.; Castorina, M.; Pisano, C. Nonpeptide integrin antagonists: RGD mimetics incorporating substituted azabicycloalkanes as amino acid replacements. Eur. J. Org. Chem. 2007, 1309-1317.
Momtaz, M.; Dewez, J.-L.; Marchand-Brynaert, J. Chemical reactivity assay and surface characterization of a poly(vinylidene fluoride microfiltration membrane (Durapore DVPP). J. Membr. Sci. 2005, 250, 29-37. (Pubitemid 40320493)
Chollet, C.; Chanseau, C.; Remy, M.; Guignandon, A.; Bareille, R.; Labrugère, C.; Bordenave, L.; Durrieu, M.-C. The effect of RGD density on osteoblast and endothelial cell behavior on RGD-grafted polyethylene terephthalate surfaces. Biomaterials 2009, 30, 711-720.
Hartman, G. D.; Egbertson, M. S.; Halczenko, W.; Laswell, W. L.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; Manno, P. D.; Lynch, R. J.; Zhang, G.; Chang, C. T.-C.; Gould, R. J. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 1992, 35, 4640-4642.
Owen, R. M.; Carlson, C. B.; Xu, J.; Mowery, P.; Fasella, E.; Kiessling, L. L. Bifunctional ligands that target cells displaying the α vβ3 integrin. ChemBioChem 2007, 8, 68-82.
Carlson, C. B.; Mowery, P.; Owen, R. M.; Dykhuizen, E. C.; Kiessling, L. L. Selective tumor cell targeting using low-affinity, multivalent interactions. ACS Chem. Biol. 2007, 2, 119-127.
Dijkgraaf, I.; Kruijtzer, J. A. W.; Frielink, C.; Soede, A. C.; Hilbers, H. W.; Oyen, W. J. G.; Corstens, F. H. M.; Liskamp, R. M. J.; Boerman, O. C. Synthesis and biological evaluation of potent αvβ 3 integrin receptor antagonists. Nucl. Med. Biol. 2006, 33, 953-961.
Müller, B.; Zerwes, H. G.; Tangemann, K.; Peter, J.; Engel, J. 2-Step binding mechanism of fribrinogen to αIIbβ 3 integrin reconstituted into planar lipid bilayers. J. Biol. Chem. 1993, 268, 6800-6808.
Vilamitjana-Amédée, J.; Bareille, R.; Rouais, F.; Caplan, A. E.; Harmand, M. F. Human bone marrow stromal cells expressing osteoblastic phenotype in vitro. Cell. Dev. Biol. 1993, 29, 699-707.
Villars, F.; Guillotin, B.; Amédée, T.; Dutoya, S.; Bordenave, L.; Bareille, R.; Amédée, J. Effect of HUVEC on human osteoprogenitor cell differentiation needs heterotypic gap junction communication. Am. J. Physiol. Cell. Physiol. 2002, 282, C775-C785.
Hariharan, P. C.; Pople, J. A. The influence of polarization functions on molecular hydrogenation energies. Theor. Chim. Acta 1973, 28, 213-217.
Dive, G.; Dehareng, D.; Ghuysen, J. M. Energy analysis of small to medium sized H-bonded complexes. Theor. Chim. Acta 1993, 85, 409-421.
Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A.; Jr., Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.;Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. Gaussian 03, revision C.02; Gaussian, Inc.: Wallingford, CT, 2004.
Pourcelle, V.; Devouge, S.; Garinot, M.; Préat, V.; Marchand-Brynaert, J. PCL-PEG-based nanoparticles grafted with GRGDS peptide: preparation and surface analysis by XPS. Biomacromolecules 2007, 8, 3977-3983.
Golledge, J.; Tumer, R. J.; Harley, S. L.; Springall, D. R.; Powell, J. T. Development of an in vitro model to study the response of saphenous vein endothelium to pulsatile arterial flow and circumferential deformation. Eur. J. Vasc. Endovasc. Surg. 1997, 13, 605-612.
